Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

Similar articles for PubMed (Select 23526920)

1.

Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Dickerson JW, Conn PJ.

Neurodegener Dis Manag. 2012 Apr 1;2(2):221-232.

2.

Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.

Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ.

Pharmacol Ther. 2000 Dec;88(3):427-35. Review.

PMID:
11337032
3.

Glutamate receptors as therapeutic targets for Parkinson's disease.

Johnson KA, Conn PJ, Niswender CM.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):475-91. Review.

4.

Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia.

Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ.

Amino Acids. 2002;23(1-3):185-91. Review.

PMID:
12373536
5.

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Duty S.

Br J Pharmacol. 2010 Sep;161(2):271-87. doi: 10.1111/j.1476-5381.2010.00882.x. Review.

6.

Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.

Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A.

Amino Acids. 2007 Feb;32(2):189-95. Epub 2006 May 22. Review.

PMID:
16715415
7.

Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.

Amalric M.

Curr Opin Pharmacol. 2015 Feb;20:29-34. doi: 10.1016/j.coph.2014.11.001. Epub 2014 Nov 19. Review.

PMID:
25462289
8.

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.

Sgambato-Faure V, Cenci MA.

Prog Neurobiol. 2012 Jan;96(1):69-86. doi: 10.1016/j.pneurobio.2011.10.005. Epub 2011 Nov 3. Review.

PMID:
22075179
9.

Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, Conn PJ.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. Epub 2003 Oct 30.

10.

Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.

Nandhu MS, Paul J, Kuruvila KP, Abraham PM, Antony S, Paulose CS.

Mol Cell Biochem. 2011 Jul;353(1-2):47-57. doi: 10.1007/s11010-011-0773-x. Epub 2011 Mar 8.

PMID:
21384157
11.

Parkinson's disease: from molecular pathways in disease to therapeutic approaches.

Thomas B.

Antioxid Redox Signal. 2009 Sep;11(9):2077-82. doi: 10.1089/ars.2009.2697.

12.

Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics.

Marino MJ, Conn PJ.

Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):239-50. Review. Erratum in: Curr Drug Target CNS Neurol Disord. 2002 Aug;1(4):1 p following 448. Conn, Jeffrey P [corrected to Conn, P Jeffrey]..

PMID:
12769617
13.

Glutamate receptors and Parkinson's disease: opportunities for intervention.

Marino MJ, Valenti O, Conn PJ.

Drugs Aging. 2003;20(5):377-97. Review.

PMID:
12696997
14.
15.

Protective and symptomatic strategies for therapy of Parkinson's disease.

Blandini F, Greenamyre JT.

Drugs Today (Barc). 1999 Jun;35(6):473-83.

PMID:
12973393
16.

Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.

Amalric M, Lopez S, Goudet C, Fisone G, Battaglia G, Nicoletti F, Pin JP, Acher FC.

Neuropharmacology. 2013 Mar;66:53-64. doi: 10.1016/j.neuropharm.2012.05.026. Epub 2012 Jun 1. Review.

PMID:
22664304
17.

Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.

Chen LW, Yung KL, Chan YS.

Curr Drug Targets. 2005 Nov;6(7):821-33. Review.

PMID:
16305461
18.

Metabotropic glutamate receptors for Parkinson's disease therapy.

Gasparini F, Di Paolo T, Gomez-Mancilla B.

Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19.

19.

Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.

Simola N, Morelli M, Pinna A.

Curr Pharm Des. 2008;14(15):1475-89. Review.

PMID:
18537671
20.

Recent developments in the pharmacological treatment of Parkinson's disease.

Tuite P, Riss J.

Expert Opin Investig Drugs. 2003 Aug;12(8):1335-52. Review.

PMID:
12882620
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk